Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2017

01-03-2017 | Letter to the Editor

Presence of risk factors does not affect outcome in early stage pediatric Hodgkin lymphoma treated with ABVD

Authors: Sainath Bhethanabhotla, Sameer Bakhshi

Published in: Annals of Hematology | Issue 3/2017

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Mauz-Körholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K et al (2015) Pediatric Hodgkin lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 33(27):2975–2985CrossRef
2.
Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R et al (2009) A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114(10):2051–2059CrossRefPubMedPubMedCentral
3.
Donaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billett AL et al (2007) Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol Off J Am Soc Clin Oncol 25(3):332–337CrossRef
4.
Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J et al (2012) Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin’s lymphoma—a report from the Children’s Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 30(26):3174–3180CrossRef
5.
Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J et al (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 20(18):3765–3771CrossRef
6.
Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ et al (2012) Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children’s Oncology Group. Pediatr Blood Cancer 59(7):1259–1265CrossRefPubMedPubMedCentral
7.
Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A et al (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study. J Clin Oncol Off J Am Soc Clin Oncol 28(23):3680–3686CrossRef
8.
Oberlin O, Leverger G, Pacquement H, Raquin MA, Chompret A, Habrand JL et al (1992 Oct) Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol Off J Am Soc Clin Oncol 10(10):1602–1608
9.
Vecchi V, Pileri S, Burnelli R, Bontempi N, Comelli A, Testi AM et al (1993) Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 72(6):2049–2057CrossRefPubMed
10.
Dieckmann K, Pötter R, Hofmann J, Heinzl H, Wagner W, Schellong G et al (2003) Does bulky disease at diagnosis influence outcome in childhood Hodgkin’s disease and require higher radiation doses? Results from the German-Austrian pediatric multicenter trial DAL-HD-90. Int J Radiat Oncol Biol Phys 56(3):644–652CrossRefPubMed
11.
Bonadonna G, Santoro A (1982 Mar) ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev 9(1):21–35CrossRefPubMed
Metadata
Title
Presence of risk factors does not affect outcome in early stage pediatric Hodgkin lymphoma treated with ABVD
Authors
Sainath Bhethanabhotla
Sameer Bakhshi
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2880-y

Other articles of this Issue 3/2017

Annals of Hematology 3/2017 Go to the issue

Letter to the Editor

Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome

Letter to the Editor

Reversion of serum VZV-IgG antibody preceding disseminated visceral varicella zoster after hematopoietic stem cell transplantation

Letter to the Editor

Evidence for a role of decitabine in the treatment of myeloid sarcoma

Original Article

Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Original Article

Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib

Letter to the Editor

Cyclin A2 as a potential differential marker of splenic diffuse red pulp small B-cell lymphoma: a report of the first case

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits